TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in electrical activity of mastication muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of local anesthetic's spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients participating in comprehensive molecular profiling
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of patients referred for cascade genetic testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of patients referred for molecularly targeted clinical trials
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Functional movement Screen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic Organ Prolapse-Quantification (POP-Q) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic Floor Distress Inventory (PFDI-20) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in [11C]-raclopride binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Measured deviation angle at the conclusion of prism adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-drug antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: change in mMS at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of nebulizations per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Indirect local concentration of nebulized TXA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic Concentration of nebulized TXA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monitoring of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Hemoglobin (Hgb) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in Lactate Dehydrogenase (LDH) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in markers of skeletal muscle metabolism GDF15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in markers of skeletal muscle metabolism FGF21
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in motor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Size of intercellular spaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of keratinocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of hyaluronic acid granules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of Hyaluronic Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Severity Grades of TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants discontinuing study treatment due to treatment related grade≥3 non-hematological adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants discontinuing study treatment due to treatment related grade≥3 adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Time to achieve 50% of maximum photoplethysmographic amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint and bone health assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall compliance of eradication medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Eradication of CRE carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Engraftment of transplanted vaginal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of 5-ALA + SFC administration
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility and acceptability of the study app
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subtle Avoidance Frequency Examination (SAFE)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in HFA-PEFF-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of HFpEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite endpoint cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac function of the right ventricle as measured by ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac function of the left ventricle as measured by ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of ventricular dysfunction as measured by strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Long-term effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance Rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Myocardial infarction type 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-hour movement behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Vascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 3-year progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: THE ABILHAND
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Call-taker crisis counseling fidelity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of Intervention Measure; AIM
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: WSLs evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of Balloon Catheter duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of participants reporting on Penetrative Intercourse
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: EEG Activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Goniometers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of participants achieving full target dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Self-scheduled a Flu Shot
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Device tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative hematocrit (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Absence of infection
Endpoint domain: Adverse events/effects
Primary endpoint: Tongue elevation strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to cervical cancer screening steps
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Measurement of urine and blood arsenic metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absenteeism and presenteeism
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: adverse events (AE) and serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: GvHD
Endpoint domain: Adverse events/effects
Primary endpoint: Immune effector cell-associated neurotoxicity syndrome (ICANs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Days Abstinent from Opioids
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sustained Relapse
Endpoint domain: Adverse events/effects
Primary endpoint: BP-lowering medications per participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of need for Heart Replacement Therapies
Endpoint domain: Mortality/survival
Primary endpoint: heart failure re-hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Percent Change From Baseline in Alkaline Phosphatase (ALP) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Inorganic Pyrophosphate (PPi) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Pyridoxal 5'-Phosphate (PLP) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking Speed (10 meter Walk Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instrumented Timed UP and GO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall Events
Endpoint domain: Adverse events/effects
Primary endpoint: Fluid requirement using Sub Clavian vein collapsibility index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Albumin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and severity of study treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients enrolled in the clinical study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of patients who remain in the clinical study to completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Relative change from baseline in body weight percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Surgical delay
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Trunk extensor endurance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bilater side bridge endurance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognition as measured by NTB total score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total radioactivity in whole blood and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Event-Free Survival (EFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Safety of OMN6 treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of OMN6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of OMN6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of OMN6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of OMN6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percent of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Caregivers' Comfort in Managing Shortness of Breath
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Caregivers' Knowledge in Delivering Liquid Medication
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Caregivers' Comfort in Using Opioids to Treat Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Study feasibility (enrollment and retention)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum tolerable dose of sildenafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BETY-Biopsychosocial Questionnaire (BETY-BQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Turkish Eating Assessment Tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Xerostomia inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multidimensional Fatigue Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Test of Mastication and Swallowing Solids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal MR Imaging of the thoracic and lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of candidiasis events
Endpoint domain: Adverse events/effects
Primary endpoint: Time between episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Recall Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Engagement in Family Check Up 4 Health (FCU4Health)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Time to recognition of cardiac arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uptake of Germline Genetic Testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes of SCORing Atopic Dermatitis (SCORAD) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Dermatology Life Quality Index (DLQI) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Heat and Cold Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Peak Oxygen Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Peak Workload
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change body fat mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Body fat free mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in aortic valve calcium (AVC) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tonsil cell characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ≥ grade 3 diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of natural odour in human CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Modified Rankin Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: volume reduction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of nodule regrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adherence to Trikafta dosing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to Multivitamin dosing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Coma Recovery Scale-revised score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in radiographic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of Teprotumumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Serum Concentration (Cmax) of Teprotumumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of osteoarthritis grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary intake assessment (24-hour dietary recall)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dietary intake assessment (food frequency questionnaire (FFQ))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants who securely stored their opioid medication during treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of participants who disposed of their unused opioid medication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Infection rate of transmetatarsal amputation site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: BTVA-C related AEs/SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Successful BTVA-C Treatment Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Local Control Evaluation per RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Anesthesia pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL change rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achievement rate to target LDL level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: great saphenous vein (SVG) grafts occlusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Area Under the Dosing Time Curve (AUC0-tau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Css,max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of early diagnosis of lung nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ocular Discomfort Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-treatment complication grade≥3
Endpoint domain: Adverse events/effects
Primary endpoint: Patient discomfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Depression and anxiety mood symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Well-being: subjective vitality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feasibility of Intervention Measure (FIM) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Networked Minds Measure (NMM) of Social Presence
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: midazolam AUC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean OAR Dose Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early molecular response (EMR) rate at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paternal confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Uptake by schools
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Uptake by participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Wound Healing size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nurses Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intensity of acute postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessed by Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of unacceptable adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete response (CR) rate
Endpoint domain: Physiological/clinical
Primary endpoint: Serum hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: sST2 biomarker level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-loss injury
Endpoint domain: Adverse events/effects
Primary endpoint: Time-loss illness
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentrations of KDT-3594 and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction during the intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction after the intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Session attendance after the intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cmax of etoricoxib in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of etoricoxib in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed nursing time for PAC infusion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Propofol injection pain (PIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free rate (PFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Community-Acquired Pneumonia (CAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Barratt Impulsiveness scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants that demonstrate hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes